Leaflet ZOREEDA CIPHALER 50mcg / 500mcg inhalation powder


Indicated for: asthma; chronic obstructive pulmonary disease

Route of administration: inhalation

Substance: salmeterol + fluticasone (beta-2 adrenergic agonist + glucocorticoid)

ATC: R03AK06 (Respiratory system | Adrenergics, inhalants | Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics)

Precautions:
Glaucoma warning
Glaucoma warning

Use caution if you have glaucoma or increased eye pressure.

Hyperglycemia
Hyperglycemia

This medicine may increase blood sugar.

Immunosuppression / infection risk
Immunosuppression / infection risk

This medicine may increase the risk of infections.

Breastfeeding warning
Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning
Pregnancy warning

Use during pregnancy only on medical advice.

Cardiac risk / QT prolongation / arrhythmias
Cardiac risk / QT prolongation / arrhythmias

This medicine may increase the risk of heart rhythm disturbances.

Salmeterol+fluticasone is a combination medication used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Salmeterol is a long-acting beta-2 adrenergic agonist that relaxes airway muscles and improves airflow. Fluticasone is an inhaled corticosteroid that reduces inflammation and prevents exacerbations.

This combination is administered via inhalation, usually twice daily, and is indicated for patients requiring both bronchodilation and anti-inflammatory control. It is effective in reducing symptoms, preventing asthma attacks, and improving quality of life.

Common side effects include throat irritation, hoarseness, oral fungal infections (candidiasis), and tremors. In rare cases, severe adverse reactions such as paradoxical bronchospasm or adrenal suppression may occur. Patients are advised to rinse their mouth after use to reduce the risk of candidiasis.

Salmeterol+fluticasone is a valuable therapeutic option for patients with chronic respiratory conditions, providing effective symptom control and prevention of exacerbations.

General data about ZOREEDA CIPHALER 50mcg / 500mcg

  • Substance: salmeterol + fluticasone
  • Date of last drug list: 01-05-2025
  • Commercial code: W71064001
  • Concentration: 50mcg / 500mcg
  • Pharmaceutical form: inhalation powder
  • Quantity: 1
  • Product type: generic
  • Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Marketing authorisation

  • Manufacturer: CIPLA EUROPE NV - BELGIA
  • Holder: CIPLA EUROPE NV - BELGIA
  • Number: 14983/2023/01
  • Shelf life: 2 years-after packing for marketing;after openinga saculetului-2 months

Concentrations available for salmeterol + fluticasone

  • 25mcg/125mcg
  • 25mcg/125mcg/dose
  • 25mcg/250mcg
  • 25mcg/250mcg/dose
  • 25mcg/50mcg
  • 25mcg/50mcg/dose
  • 50mcg/100mcg
  • 50mcg/250mcg
  • 50mcg/250mcg/dose
  • 50mcg/500mcg
  • 50mcg/500mcg/dose
  • 50mg/100mg
  • 50mg/250mg
  • 50mg/500mg